GSK plcGSKNYSE
Loading
EPS Growth Under PressureDecelerating
Percentile Rank15
Year-over-Year Change
Year-over-year earnings per share growth rate
Percentile
P15
Within normal range
vs 3Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -68.00% |
| Q4 2025 | 38.89% |
| Q2 2025 | -10.00% |
| Q1 2025 | 300.00% |
| Q4 2024 | 804.23% |
| Q3 2024 | -104.90% |
| Q2 2024 | 11.54% |
| Q1 2024 | 201.27% |
| Q4 2023 | -76.03% |
| Q3 2023 | -10.00% |
| Q2 2023 | 8.11% |
| Q1 2023 | 0.00% |
| Q4 2022 | 94.74% |
| Q3 2022 | -9.52% |
| Q2 2022 | -53.33% |
| Q1 2022 | 136.84% |
| Q4 2021 | -34.48% |
| Q3 2021 | -17.14% |
| Q2 2021 | 29.63% |
| Q1 2021 | 58.82% |
| Q4 2020 | -45.16% |
| Q3 2020 | -45.61% |
| Q2 2020 | 46.15% |
| Q1 2020 | 18.18% |
| Q4 2019 | -15.38% |
| Q3 2019 | 62.50% |
| Q2 2019 | 14.29% |
| Q1 2019 | -32.26% |
| Q4 2018 | -13.89% |
| Q3 2018 | 227.27% |
| Q2 2018 | -21.43% |
| Q1 2018 | 200.00% |
| Q4 2017 | -145.16% |
| Q3 2017 | 769.55% |
| Q2 2017 | -117.15% |
| Q1 2017 | 307.24% |
| Q4 2016 | -68.43% |
| Q3 2016 | 290.91% |
| Q2 2016 | -251.72% |
| Q1 2016 | 179.23% |